Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present)

23 Oct 2019

Abstract excerpt

BACKGROUND: Mouse Double Minute 2 protein (MDM2) is a cellular regulator of p53 tumor suppressor (p53). Inhibition of the interaction between MDM2 and p53 proteins is a promising anticancer therapy. OBJECTIVE: This updated patent review is an attempt to compile the research and achievements of the various researchers working on small molecule MDM2 inhibitors from 2010 to date. We provide an outlook into the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biological Research and Disease Studies
Share to Cancer-related Molecular Pathways
Share to Diverse Scientific Research Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31642413
DOI: 10.2174/1574892814666191022163540

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present)PMID 31642413Read ↗

Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present)Semantic proximity Read ↗

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trialsSemantic proximity Read ↗

Small Molecule Inhibitors of the p53-MDM2Semantic proximity Read ↗

Patented inhibitors of p53–Mdm2 interaction (2006 – 2008)Semantic proximity Read ↗

p53–Mdm2 inhibitors: patent review (2009 – 2010)Semantic proximity Read ↗

Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?Semantic proximity Read ↗

Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatmentSemantic proximity Read ↗

A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)Semantic proximity Read ↗

Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of ActionSemantic proximity Read ↗

Targeting the MDM2-p53 Interaction for Cancer TherapySemantic proximity Read ↗

MDM2: current research status and prospects of tumor treatmentSemantic proximity Read ↗

Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be AddressedSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.